JP2003506389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003506389A5 JP2003506389A5 JP2001514908A JP2001514908A JP2003506389A5 JP 2003506389 A5 JP2003506389 A5 JP 2003506389A5 JP 2001514908 A JP2001514908 A JP 2001514908A JP 2001514908 A JP2001514908 A JP 2001514908A JP 2003506389 A5 JP2003506389 A5 JP 2003506389A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- compound
- embedded image
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- -1 Phenyl Chemical group 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14770699P | 1999-08-06 | 1999-08-06 | |
| US60/147,706 | 1999-08-06 | ||
| PCT/US2000/021503 WO2001010383A2 (en) | 1999-08-06 | 2000-08-04 | Caspase inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003506389A JP2003506389A (ja) | 2003-02-18 |
| JP2003506389A5 true JP2003506389A5 (enExample) | 2011-06-30 |
Family
ID=22522602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001514908A Pending JP2003506389A (ja) | 1999-08-06 | 2000-08-04 | カスパーゼ阻害剤およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6632962B2 (enExample) |
| EP (1) | EP1163208B1 (enExample) |
| JP (1) | JP2003506389A (enExample) |
| AT (1) | ATE266623T1 (enExample) |
| AU (1) | AU6894800A (enExample) |
| DE (1) | DE60010675T2 (enExample) |
| DK (1) | DK1163208T3 (enExample) |
| ES (1) | ES2219381T3 (enExample) |
| PT (1) | PT1163208E (enExample) |
| TW (1) | TWI281910B (enExample) |
| WO (1) | WO2001010383A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1165490B1 (en) | 1999-03-16 | 2006-08-16 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| AU4213500A (en) | 1999-04-09 | 2000-11-14 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
| BR0013666A (pt) | 1999-08-27 | 2002-05-14 | Cytovia Inc | "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| AT413485B (de) * | 2001-04-09 | 2006-03-15 | Hemoteq Gmbh | Mit einem pharmazeutikum beschichteter stent |
| US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
| WO2003068242A1 (en) | 2002-02-11 | 2003-08-21 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
| US7960398B2 (en) | 2002-04-19 | 2011-06-14 | Vertex Pharmaceuticals Incorporated | Regulation of TNF-alpha |
| GB2389580A (en) * | 2002-06-12 | 2003-12-17 | Bayer Ag | 2-Naphthamide PGI2 antagonists |
| US20060217299A1 (en) * | 2003-02-24 | 2006-09-28 | Hirofumi Doi | Degradation inhibitor for hepatitis b virus x interacting protein |
| CA2524882A1 (en) * | 2003-05-06 | 2004-11-25 | Cytovia, Inc. | Protease inhibitors for coronaviruses and sars-cov and the use thereof |
| AU2003902704A0 (en) * | 2003-05-29 | 2003-06-19 | Crc For Waste Management And Pollution Control Limited Of Unsw | Process for producing a nanoscale zero-valent metal |
| IL158599A0 (en) * | 2003-10-26 | 2004-05-12 | Yeda Res & Dev | Methods of modulating hematopoiesis |
| WO2005117846A2 (en) | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
| EP1723124A1 (en) * | 2004-02-18 | 2006-11-22 | Georgia Tech Research Corporation | Propenoyl hydrazides |
| CA2768700C (en) * | 2004-03-12 | 2014-04-29 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
| US20060128696A1 (en) * | 2004-05-15 | 2006-06-15 | Annamaria Vezzani | Treating seizures using ice inhibitors |
| FR2878522B1 (fr) * | 2004-12-01 | 2008-04-18 | Merck Sante Soc Par Actions Si | Nouveaux inhibiteurs specifiques de la caspas-10 |
| ATE529430T1 (de) * | 2005-07-28 | 2011-11-15 | Vertex Pharma | Caspase-hemmer-propharmaka |
| US8828950B2 (en) * | 2007-05-01 | 2014-09-09 | Cedars-Sinai Medical Center | Caspase inhibitors in the treatment of infection-associated preterm delivery |
| JP6006908B2 (ja) | 2010-11-05 | 2016-10-12 | ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ | Ｉｃｅ阻害化合物およびその使用 |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| US9592223B2 (en) | 2012-11-09 | 2017-03-14 | Cornell University | Small molecule inhibitors of MALT1 |
| SG11201609256SA (en) | 2014-05-12 | 2016-12-29 | Conatus Pharmaceuticals Inc | Treatment of the complications of chronic liver disease with caspase inhibitors |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| US20190022043A1 (en) | 2015-12-31 | 2019-01-24 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
| WO2018065902A1 (en) | 2016-10-05 | 2018-04-12 | Novartis Ag | Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
| TWI764977B (zh) | 2017-01-23 | 2022-05-21 | 大陸商正大天晴藥業集團股份有限公司 | 作爲ｃａｓｐａｓｅ抑制劑的聯環化合物、含有其的藥物組合物及其應用 |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
| EP4301396A1 (en) | 2021-03-03 | 2024-01-10 | The United States of America, as represented by the Secretary, Department of Health and Human Services | La protien as a novel regulator of osteoclastogenesis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0618223A3 (en) * | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
| CA2237314A1 (en) * | 1996-09-12 | 1998-03-19 | Donald S. Karanewsky | Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes |
| US6242422B1 (en) * | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| EP1165490B1 (en) * | 1999-03-16 | 2006-08-16 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| CA2380935A1 (en) * | 2000-05-23 | 2001-11-29 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| AU2001275279B2 (en) * | 2000-06-07 | 2007-01-04 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
-
2000
- 2000-08-04 DK DK00957311T patent/DK1163208T3/da active
- 2000-08-04 AT AT00957311T patent/ATE266623T1/de not_active IP Right Cessation
- 2000-08-04 PT PT00957311T patent/PT1163208E/pt unknown
- 2000-08-04 ES ES00957311T patent/ES2219381T3/es not_active Expired - Lifetime
- 2000-08-04 DE DE60010675T patent/DE60010675T2/de not_active Expired - Lifetime
- 2000-08-04 EP EP00957311A patent/EP1163208B1/en not_active Expired - Lifetime
- 2000-08-04 AU AU68948/00A patent/AU6894800A/en not_active Abandoned
- 2000-08-04 WO PCT/US2000/021503 patent/WO2001010383A2/en not_active Ceased
- 2000-08-04 JP JP2001514908A patent/JP2003506389A/ja active Pending
- 2000-08-05 TW TW089115790A patent/TWI281910B/zh active
-
2001
- 2001-04-03 US US09/834,052 patent/US6632962B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003506389A5 (enExample) | ||
| JP2003535865A5 (enExample) | ||
| JP2003534325A5 (enExample) | ||
| JP2004509120A5 (enExample) | ||
| CA2393710A1 (en) | Caspase inhibitors and uses thereof | |
| JP2005504811A5 (ja) | 置換ペンタセン化合物、半導体デバイス及び物品 | |
| ES2117795T3 (es) | Derivados de acetamida y su uso como modificadores del comportamiento de toma alimentaria. | |
| JP2002526501A5 (enExample) | ||
| IL158818A0 (en) | Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases | |
| WO2005037781A3 (fr) | Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
| CA2119556A1 (en) | Substituted aryl- and heteroaryl-phenyloxazolidinones | |
| KR970015579A (ko) | 테트라졸 화합물 | |
| CA2634811A1 (en) | Novel modifications to 2-amino-4-(4-fluorobenzylamino) -1- ethoxycarbonyl-aminobenzene and processes for preparing said compound | |
| JP2009519993A5 (enExample) | ||
| CA2288789A1 (en) | Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands | |
| NO20053211L (no) | Forbindelser for behandling av metabolske forstyrrelser. | |
| JP2019513745A5 (enExample) | ||
| JP2019510794A5 (enExample) | ||
| WO2002008203A3 (en) | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 | |
| JP2010530002A5 (enExample) | ||
| JPH09124479A5 (enExample) | ||
| JP2010535706A5 (enExample) | ||
| JP2006523241A5 (enExample) | ||
| JP2007525503A5 (enExample) | ||
| CA2659084A1 (en) | Caspase inhibitors based on pyridazinone scaffold |